AMERICAN JOURNAL OF OPHTHALMOLOGY美国眼科学杂志
AMERICAN JOURNAL OF OPHTHALMOLOGY(英文缩写 AM J OPHTHALMOL),ISSN 0002-9394,eISSN 1879-1891,中文译名:美国眼科学杂志 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-11-01 至 2026-10-31，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 5.488 | Q1 |
| 2022 | 4.200 | Q1 |
| 2023 | 4.100 | Q1 |
| 2024 | 4.200 | Q1 |
| 2025 | 4.700 | Q1 |
AMERICAN JOURNAL OF OPHTHALMOLOGY 最新收录文献
-
3. Reply to Comment on: Influence of the Corneal Posterior-to-Anterior Radius Ratio on IOL Power Prediction Using Standard and Total Keratometry.
3. 回复评论：角膜后前半径比对使用标准角膜曲率测量和全角膜曲率测量的IOL度数预测的影响PMID:日期:2026-10-01该文献暂无摘要。
-
4. Subbasal Nerve Plexus Alterations Following Ocular Proton Therapy in Uveal Melanoma Assessed by Corneal Confocal Microscopy.
4. 通过角膜共聚焦显微镜评估葡萄膜黑色素瘤眼部质子治疗后角膜上皮下神经丛的改变PMID:日期:2026-10-01To evaluate longitudinal changes in the subbasal nerve plexus (SNP) after ocular proton therapy (OPT) in eyes with uveal melanoma and associated changes in corneal sensitivity, cell density, and patient-reported outcomes. Prospective clinical cohort study. Fifty-eight patients (58 eyes) with uveal melanoma were enrolled; 54 had evaluable baseline corneal confocal microscopy images, and 40 formed the longitudinal analysis cohort. Follow-up data were available for 30 patients at 3 months and 27 patients at 12 months. Corneal confocal microscopy was used to assess SNP parameters and cell density. Corneal sensitivity was measured with a Cochet-Bonnet aesthesiometer. Patient-reported outcomes were assessed using the German Ocular Surface Disease Index (OSDI) and selected domains from the German version of the NEI VFQ-25. Examinations were performed before OPT and at 3 and 12 months after OPT. Primary outcome measures were changes in corneal nerve fiber density (CNFD), corneal nerve branch density (CNBD), and corneal nerve fiber length (CNFL). Secondary outcome measures included corneal nerve fiber tortuosity (CNFT), cell density, corneal sensitivity, OSDI, and selected NEI VFQ-25 domains. CNFD decreased from 18.2 to 11.4 (3 months) and 12.7 no./mm² (12 months) (P = .002 and .001). CNBD decreased from 23.9 to 13.5 and 15.8 no./mm² (P = .012 and .040), and CNFL from 11.0 to 6.2 and 7.3 mm/mm² (both P < .001). Nerve loss was associated with treatment-related exposure, particularly the clinical target volume. CNFT decreased at 3 months (P = .018) and approached baseline at 12 months (P = .28). Corneal sensitivity did not change significantly. OSDI increased at 12 months (P = .049). After Benjamini-Hochberg correction, the 3-month CNFT, 12-month OSDI, and 12-month cell density changes were no longer significant. Among NEI VFQ-25 domains, only peripheral vision declined (84 to 68; P = .006). OPT was associated with marked reduction of SNP parameters, with only partial recovery by 12 months. Greater nerve loss was associated with larger treatment volumes and greater corneal irradiation. Cell density and corneal sensitivity remained unchanged, whereas patient-reported outcomes did not consistently reflect structural denervation.
-
5. Multimodal Characterization of Mid-phase Hyperfluorescent Plaques on Indocyanine Green Angiography in Central Serous Chorioretinopathy- MICRoN report number 27.
5. 吲哚菁绿血管造影中中期高荧光斑块在中心性浆液性脉络膜视网膜病变中的多模态特征——MICRoN第27号报告PMID:日期:2026-10-01To characterize the phenotypic spectrum of mid-phase hyperfluorescent plaques (MPHPs) on indocyanine green angiography (ICGA) in eyes with central serous chorioretinopathy (CSCR) and to evaluate their relationship with corresponding optical coherence tomography (OCT) features. Retrospective, observational multicenter cohort study. Forty eyes of 29 patients, 25 (86.2%) male and 4 (13.8%) female, with CSCR and a median follow-up of 39 months. Imaging features on ICGA and macular OCT were documented at baseline and follow-up. MPHPs were classified into four 'types': 'without-dots', 'with-dots', 'hypo-center' and 'with-leak'. When multiple types coexisted within one plaque, a single mutually exclusive 'stage' was assigned according to the highest-ranking angiographic feature present, ranked by the hierarchical structure of the features on ICGA. Corresponding OCT features at each MPHP site included subretinal fluid (SRF), ellipsoid zone and retinal pigment epithelium (EZ/RPE) irregularity, pigment epithelial detachment (PED), hyperreflective foci (HRF), outer nuclear layer (ONL) thinning, double-layer sign, RPE atrophy, RPE infrared abnormalities, pachyvessels and choroidal thickness. Associations were estimated using generalized estimating equations clustered at the patient level, with correction for multiple comparisons. Transitions between stages and predictors of new leak onset were assessed over follow-up. OCT structural features across MPHP phenotypes. A total of 112 MPHPs were present at baseline, of which 92 had a co-registered OCT B-scan. EZ/RPE irregularity was near-universal (82 of 92, 89.1%) and did not differ across stages (odds ratio [OR] 0.75, q = 0.394. SRF showed the strongest gradient across stages, rising to 100% at the 'with-leak' stage (OR 5.34, 95% CI 2.90-9.84; q < 0.001), followed by HRF (OR 1.66; q < 0.001), PED (OR 1.99; q = 0.019) and ONL thinning (OR 1.93; q = 0.039). At the sites where de novo plaques later appeared, EZ/RPE irregularity was already present in 8 of 10 assessable locations, whereas no other structural feature was. The most common transition between stages was from 'with-dots' to 'hypo-center'; plaques at the 'hypo-center' stage were the most stable (78.3%) and showed the lowest rates of progression to a higher stage. MPHPs are dynamic imaging features in CSCR, and structural involvement on OCT increases in proportion to the angiographic complexity of the plaque. EZ/RPE irregularity was present in nearly all plaques, preceded their appearance, and did not vary across stages, suggesting that it marks a susceptible feature at the level of plaques. These findings support the role of MPHPs as focal sites of disease activity within the hyperpermeable choroid.
-
6. Teprotumumab for Thyroid Eye Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials and Real-World Studies.
6. 替妥木单抗治疗甲状腺眼病：随机对照试验与真实世界研究的系统评价与荟萃分析PMID:日期:2026-09-29Teprotumumab is the first FDA-approved biologic for moderate-to-severe thyroid eye disease (TED). Although efficacy has been established in randomized controlled trials (RCTs), real-world studies (RWS) have reported different efficacy and safety patterns, supporting an updated synthesis. A comprehensive assessment of teprotumumab across trials and routine clinical practice is needed to guide treatment decisions. This systematic review and meta-analysis included RCTs and RWS evaluating intravenous teprotumumab in adults with TED and reporting at least one prespecified efficacy or safety outcome. Other anti-IGF-1R RCTs were used only in supplementary class analyses. PubMed, Embase, Web of Science, and the Cochrane Library were searched from inception to August 10, 2026. Two reviewers independently screened studies, extracted data, and assessed risk of bias using the Cochrane RoB 2 tool and Joanna Briggs Institute criteria. Fixed- or random-effects models were selected according to heterogeneity. Risk ratios were used for dichotomous outcomes, mean differences for continuous outcomes, and proportions for single-arm RWS. Certainty was evaluated using GRADE. The protocol was registered in PROSPERO (CRD420251152338). Thirty-six studies (6 RCTs and 30 RWS) were included; 4 RCTs evaluated teprotumumab and 2 evaluated other anti-IGF-1R antibodies. Proptosis response favored teprotumumab in RCTs (risk ratio, 4.55; 95% confidence interval, 2.52-8.23) and was achieved by 82% of patients in RWS (95% confidence interval, 0.78-0.86; 11 studies, 482 patients). Diplopia response also favored teprotumumab in RCTs (risk ratio, 2.13; 95% confidence interval, 1.51-2.98), while 60% of patients improved in RWS (95% confidence interval, 0.51-0.68; 6 studies, 204 patients). Hyperglycemia was more frequent with teprotumumab in RCTs (risk ratio, 2.67; 95% confidence interval, 1.04-6.85) and occurred in 17% of patients in RWS (13 studies, 671 patients). Hearing impairment was also increased in RCTs (risk ratio, 4.05; 95% confidence interval, 1.50-10.96) and occurred in 18% of patients in RWS (13 studies, 592 patients). Teprotumumab improves proptosis and diplopia across study designs, but hyperglycemia and hearing impairment in real-world practice warrant appropriate patient selection and monitoring.
-
7. 5-Year Following Up of the Treatment Effects of Plaque Brachytherapy for Circumscribed Choroidal Haemangioma in Pediatric Patients.
7. 儿童局限性脉络膜血管瘤斑块近距离放射治疗效果的5年随访PMID:日期:2026-09-29To compare the long-term clinical outcomes and anatomical regression kinetics of pediatric versus adult patients with circumscribed choroidal hemangioma (CCH) following I-125 plaque brachytherapy. Retrospective clinical cohort study. This retrospective study included pediatric patients and adult controls diagnosed with symptomatic CCH and treated with I-125 plaque brachytherapy. Clinical and imaging data, including best-corrected visual acuity (BCVA), tumor height, and largest basal diameter (LBD), were analyzed at baseline and at 1, 6 months, 1, 2, and 5 years post-treatment. The primary outcome was the rate of tumor height reduction, and secondary outcomes included subretinal fluid (SRF) resolution and functional visual recovery. A total of 50 eyes from pediatric patients and 97 eyes from adults patients were evaluated. At baseline, the pediatric group exhibited significantly greater mean tumor height (6.45 ± 1.87mm) compared to the adult group (4.46 ± 1.46 mm, P < 0.05). Following brachytherapy, the pediatric cohort demonstrated significantly faster anatomical regression, with higher height reduction rates at 1, 6, 12, and 24 months (P < 0.01). By the 5-year following up, the cumulative height reduction was comparable between the two groups. In both cohorts, anatomical regression was characterized by more significant vertical collapse than changes in LBD. Most SRF resolved after 3 months of the surgery, while only 3 SRF cases did not resolve among pediatric patients after brachytherapy. Functional outcomes were favorable, with over 60% of patients achieving a visual improvement of >2 Snellen lines. Although children regressed faster anatomically, the final BCVA at 5 years showed no significant difference between the age groups (P > 0.05). Pediatric CCH demonstrated a more rapid anatomical response to I-125 plaque brachytherapy than adult, although the greater absolute tumor regression in pediatric patients should be interpreted in the context of greater baseline tumor thickness and enhanced radiosensitivity. Despite differences in the timing and magnitude of regression, plaque brachytherapy provided substantial tumor control and visual benefits in both pediatric and adult patients. Timely intervention of brachytherapy in pediatric cases may facilitate resolution of exudation and help preserve visual function.
-
8. Structure-function associations in eyes with Early Atrophic Age-related Macular Degeneration.
PMID:日期:2026-09-26To characterize baseline structure-function relationships in eyes with early atrophic age-related macular degeneration (AMD) and to identify functional outcomes that best reflect structural disease burden. Cross-sectional study PARTICIPANTS: A total of 87 eyes from 87 participants enrolled in the ongoing prospective observational study of early atrophic AMD (ClinicalTrials.gov NCT05959005), with incomplete or complete retinal pigment epithelium and outer retinal atrophy and total atrophic lesion size ≤ 1.27 mm² METHODS: Structural metrics derived from multimodal imaging included fundus autofluorescence (FAF)-defined geographic atrophy (GA) lesion size (total and targeted), targeted hypertransmission size, and distance to the fovea (DTF) from the lesion border. Structure-function relationships were evaluated using correlations and univariable linear regressions with multiple-comparison adjustment. Best-corrected visual acuity (BCVA), low-luminance visual acuity (LLVA), Moorfields Acuity Test (MAT), reading acuity and reading speed, and mesopic and dark-adapted (DA) cyan fundus-controlled perimetry (FCP) using fixed and lesion-targeted macular patterns. Lesion size-based structural metrics showed the strongest associations with FCP outcomes. In eyes with FAF-defined GA (n = 38), each doubling of targeted GA lesion size was associated with a 3.55 dB decrease in mean targeted mesopic sensitivity and 3.65 dB in mean targeted DA sensitivity (all P < 0.001). Similarly, doubling of targeted hypertransmission size (n = 81) was associated with decreases of 1.65 dB and 1.97 dB in mean targeted mesopic and DA sensitivities, respectively (both P < 0.001; correlations up to ρ = -0.66). In contrast, central visual and reading outcomes were primarily associated with lesion topography. Greater DTF was associated with better BCVA, LLVA, and MAT (approximately 4 to 5 letters per mm) and improved reading acuity (-0.11 logRAD per mm; all adjusted P < 0.05), whereas lesion size-based metrics showed no consistent significant association with these outcomes. In early atrophic AMD, lesion size and hypertransmission extent are closely linked to localized FCP sensitivity loss, whereas central visual acuity and reading outcomes are determined by lesion proximity to the fovea. This domain-specific separation supports targeted FCP as a sensitive endpoint for detecting structure-related functional change in early atrophic AMD.
-
9. Organism-Specific Clinical Features and Outcomes of Culture-Positive Endogenous Endophthalmitis: A Multicenter Cohort Study Over 12 Years.
PMID:日期:2026-09-26Evaluate differences in presentation, management, and outcomes of culture-positive endogenous endophthalmitis by microbial pathogen. Retrospective multicenter clinical cohort study PARTICIPANTS: Eyes with a clinical diagnosis of endogenous endophthalmitis that underwent anterior chamber paracentesis, intravitreal aspiration, or pars plana vitrectomy (PPV) and intravitreal injection of antimicrobials with no recent exogenous risk factors. Clinical presentation, culture characteristics, treatment and outcomes for culture-positive endogenous endophthalmitis from 2012-2024 at nine academic tertiary referral centers stratified by microbial pathogen were reported. Multivariable mixed-effects models were used to determine predictors of final visual acuity (VA). Final VA, retinal detachment, enucleation. 305 eyes from 261 patients were included: Staphylococcus aureus 115 (37.7%), Streptococcus 41 (13.4%), other gram-positive 29 (9.5%), gram-negative 47 (15.4%), fungal 59 (19.3%), and polymicrobial 14 (4.6%) infections. Blood cultures were positive in 202/305 eyes (66.2%), vitreous in 95 (31.1%), and aqueous in 27 (8.9%); concordant organism growth in paired blood and eye cultures occurred in 24/39 cases (62%). Fungal cases had higher rates of immunosuppression and intravenous drug use (p<0.05), while gram-negative cases more often had urinary sources (p<0.001). Presenting and final VA varied across groups (presenting mean logMAR 1.78-2.14 for most bacteria vs 1.30 for fungal, p<0.001; final mean logMAR 1.31-1.75 for bacteria vs 1.13 for fungal, p=0.06). Retinal detachment was most frequent with Staphylococcus aureus and Streptococcus. Enucleation was highest with gram-negative organisms (27.7%), driven by Serratia (85.7%, p=0.05). In adjusted mixed-effects models, worse presenting VA was the most consistent predictor of poorer final VA across groups; in Staphylococcus aureus and Streptococcus infections, systemic infection source, culture positivity, and need for PPV were predictors of final VA. In this multicenter cohort, organism groups were associated with distinct presentations, sources, management, and outcomes. Low intraocular culture yield and imperfect concordance with blood cultures complicate pathogen-directed therapy. Presenting VA is the dominant prognostic factor, but gram-negative infections-particularly Serratia-carry markedly higher risk of globe loss. These findings support organism-informed clinical decision-making and highlight the need for improved intraocular diagnostics and targeted interventions.
-
10. Prevalence, Ocular Manifestations, and Treatment Response in Post-Bariatric Vitamin A Deficiency: A Systematic Review and Meta-Analysis.
PMID:日期:2026-09-24To estimate procedure-specific prevalence of biochemical vitamin A deficiency after bariatric surgery and synthesize ocular manifestations, postoperative latency, and response to vitamin A repletion. As bariatric surgery volume continues to rise, recognition of procedure-specific vitamin A deficiency and its ocular manifestations may improve ophthalmic surveillance, earlier diagnosis, and timely repletion in post-bariatric patients. Following PROSPERO registration (CRD420261329094), we did a systematic review of MEDLINE, Embase, the Cochrane Central Register of Controlled Trials, Scopus, and Web of Science through March 2026 for studies reporting vitamin A status or ocular manifestations after bariatric surgery. Risk of bias was evaluated with the Cochrane RoB 2, ROBINS-I, and Joanna Briggs Institute checklists; the overall certainty of evidence was assessed with the GRADE framework. Of 1,574 abstracts screened, 27 reports representing 21 unique studies met inclusion criteria; 18 contributed quantitative data, of which 9 nonpregnancy surveillance cohorts (455 tested participants) entered the prevalence meta-analysis. Prevalence was 18.0% after Roux-en-Y gastric bypass (RYGB), 59.0% after biliopancreatic diversion (BPD), 37.8% after BPD with duodenal switch (BPD-DS), and 42.5% after jejunoileal bypass (JIB); the pooled estimate across these heterogeneous procedures and study-defined retinol thresholds was 26.1% (95% CI, 18.5-35.4), reported as a secondary summary. Pregnancy-specific post-RYGB prevalence was 63.3% (95% CI, 43.9-80.1). Night blindness prevalence was 60.1% in active/formal non-overlapping cohorts with symptom denominators. Median latency to ocular presentation was 5 years after RYGB and 14 to 27 years after BPD-DS, JIB, or revisional procedures (19 patients). Among 14 post-bariatric treatment-response records with assessable ocular outcomes, 13 (93%) improved or resolved. Among the procedures with adequate data, vitamin A deficiency is procedure-specific and common during pregnancy after RYGB. Ocular disease may present years to decades after surgery, but often improves when deficiency is recognized and treated. Certainty was limited by heterogeneity, the small number of cohorts for some procedure subgroups, and selective reporting of ocular outcomes. Nyctalopia, ocular surface disease, atypical outer retinal findings, or unexplained visual decline in a post-bariatric patient warrant prompt serum retinol testing and coordinated nutritional management regardless of the interval since surgery.